サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1421014

バイオ医薬品CDMOの世界市場：考察と予測 (～2030年)

Global Biopharmaceutical CDMO Market Insights, Forecast to 2030
出版日: | 発行: QYResearch | ページ情報: 英文 153 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
バイオ医薬品CDMOの世界市場：考察と予測 (～2030年)
出版日: 2024年02月06日
発行: QYResearch
ページ情報: 英文 153 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオ医薬品CDMOの市場規模は、2024年の281億6,000万米ドルから、予測期間中は13.14%のCAGRで推移し、2030年には590億5,000万米ドルの規模に成長すると予測されています。

当レポートでは、世界のバイオ医薬品CDMOの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、タイプ・用途別の内訳、地域・主要国別の詳細分析、競合環境、市場シェア、ランキング、主要企業のプロファイルなどをまとめています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析：タイプ別
    • 成長率：2019 vs 2023 vs 2030
    • 細胞および遺伝子治療
    • 抗体
    • ワクチン
    • その他
  • 用途別市場
    • 市場シェア：2019 vs 2023 vs 2030
    • 中小企業
    • 大企業
  • 前提と制限
  • 調査目的
  • 調査年数

第2章 世界の成長動向

  • 市場の展望
  • 成長動向：地域別
    • 市場規模：2019 vs 2023 vs 2030
    • 市場規模の推移
    • 市場規模の予測
  • 市場力学
    • 業界の動向
    • 市場促進要因
    • 市場の課題
    • 市場抑制要因

第3章 競合情勢：主要企業別

  • 収益・収益シェア：企業別
  • 市場シェア：企業タイプ別
  • 世界主要企業：収益ランキング
  • 市場集中率
  • 世界の主要企業：本社およびサービスエリア
  • 世界の主要企業：参入日
  • M&A・拡張計画

第4章 バイオ医薬品CDMOの内訳データ：タイプ別

  • 市場規模の推移・予測

第5章 バイオ医薬品CDMOの内訳データ：用途別

  • 市場規模の推移・予測

第6章 北米

第7章 欧州

第8章 アジア太平洋

第9章 ラテンアメリカ

第10章 中東・アフリカ

第11章 主要企業のプロファイル

  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • WuXi AppTech
  • Recipharm
  • Thermo Fisher
  • AGC Biologics
  • Rentschler Biopharma
  • KBI Biopharma
  • Siegfried
  • Aenova Group
  • GenScript
  • ProBioGen
  • Northway Biotech
  • 3P Biopharmaceuticals

第12章 アナリストによる見解・総論

第13章 付録

図表

List of Tables

  • Table 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
  • Table 2. Key Players of Cell and Gene Therapies
  • Table 3. Key Players of Antibodies
  • Table 4. Key Players of Vaccines
  • Table 5. Key Players of Other
  • Table 6. Global Biopharmaceutical CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
  • Table 7. Global Biopharmaceutical CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
  • Table 8. Global Biopharmaceutical CDMO Market Size by Region (2019-2024) & (US$ Million)
  • Table 9. Global Biopharmaceutical CDMO Market Share by Region (2019-2024)
  • Table 10. Global Biopharmaceutical CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
  • Table 11. Global Biopharmaceutical CDMO Market Share by Region (2025-2030)
  • Table 12. Biopharmaceutical CDMO Market Trends
  • Table 13. Biopharmaceutical CDMO Market Drivers
  • Table 14. Biopharmaceutical CDMO Market Challenges
  • Table 15. Biopharmaceutical CDMO Market Restraints
  • Table 16. Global Biopharmaceutical CDMO Revenue by Players (2019-2024) & (US$ Million)
  • Table 17. Global Biopharmaceutical CDMO Market Share by Players (2019-2024)
  • Table 18. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2023)
  • Table 19. Global Biopharmaceutical CDMO Industry Ranking 2022 VS 2023
  • Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Revenue (CR5) & (2019-2024)
  • Table 21. Global Key Players of Biopharmaceutical CDMO, Headquarters and Area Served
  • Table 22. Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry
  • Table 23. Mergers & Acquisitions, Expansion Plans
  • Table 24. Global Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
  • Table 25. Global Biopharmaceutical CDMO Revenue Market Share by Type (2019-2024)
  • Table 26. Global Biopharmaceutical CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
  • Table 27. Global Biopharmaceutical CDMO Revenue Market Share by Type (2025-2030)
  • Table 28. Global Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
  • Table 29. Global Biopharmaceutical CDMO Revenue Market Share by Application (2019-2024)
  • Table 30. Global Biopharmaceutical CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
  • Table 31. Global Biopharmaceutical CDMO Revenue Market Share by Application (2025-2030)
  • Table 32. North America Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
  • Table 33. North America Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
  • Table 34. North America Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
  • Table 35. North America Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
  • Table 36. North America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
  • Table 37. North America Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
  • Table 38. North America Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
  • Table 39. Europe Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
  • Table 40. Europe Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
  • Table 41. Europe Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
  • Table 42. Europe Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
  • Table 43. Europe Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
  • Table 44. Europe Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
  • Table 45. Europe Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
  • Table 46. Asia-Pacific Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
  • Table 47. Asia-Pacific Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
  • Table 48. Asia-Pacific Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
  • Table 49. Asia-Pacific Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
  • Table 50. Asia-Pacific Biopharmaceutical CDMO Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
  • Table 51. Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2019-2024) & (US$ Million)
  • Table 52. Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2025-2030) & (US$ Million)
  • Table 53. Latin America Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
  • Table 54. Latin America Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
  • Table 55. Latin America Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
  • Table 56. Latin America Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
  • Table 57. Latin America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
  • Table 58. Latin America Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
  • Table 59. Latin America Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
  • Table 60. Middle East and Africa Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million)
  • Table 61. Middle East and Africa Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million)
  • Table 62. Middle East and Africa Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million)
  • Table 63. Middle East and Africa Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million)
  • Table 64. Middle East and Africa Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
  • Table 65. Middle East and Africa Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million)
  • Table 66. Middle East and Africa Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million)
  • Table 67. Lonza Company Details
  • Table 68. Lonza Business Overview
  • Table 69. Lonza Biopharmaceutical CDMO Product
  • Table 70. Lonza Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 71. Lonza Recent Development
  • Table 72. Catalent Company Details
  • Table 73. Catalent Business Overview
  • Table 74. Catalent Biopharmaceutical CDMO Product
  • Table 75. Catalent Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 76. Catalent Recent Development
  • Table 77. Samsung Biologics Company Details
  • Table 78. Samsung Biologics Business Overview
  • Table 79. Samsung Biologics Biopharmaceutical CDMO Product
  • Table 80. Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 81. Samsung Biologics Recent Development
  • Table 82. FUJIFILM Diosynth Biotechnologies Company Details
  • Table 83. FUJIFILM Diosynth Biotechnologies Business Overview
  • Table 84. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Product
  • Table 85. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 86. FUJIFILM Diosynth Biotechnologies Recent Development
  • Table 87. Boehringer Ingelheim Company Details
  • Table 88. Boehringer Ingelheim Business Overview
  • Table 89. Boehringer Ingelheim Biopharmaceutical CDMO Product
  • Table 90. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 91. Boehringer Ingelheim Recent Development
  • Table 92. WuXi AppTech Company Details
  • Table 93. WuXi AppTech Business Overview
  • Table 94. WuXi AppTech Biopharmaceutical CDMO Product
  • Table 95. WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 96. WuXi AppTech Recent Development
  • Table 97. Recipharm Company Details
  • Table 98. Recipharm Business Overview
  • Table 99. Recipharm Biopharmaceutical CDMO Product
  • Table 100. Recipharm Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 101. Recipharm Recent Development
  • Table 102. Thermo Fisher Company Details
  • Table 103. Thermo Fisher Business Overview
  • Table 104. Thermo Fisher Biopharmaceutical CDMO Product
  • Table 105. Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 106. Thermo Fisher Recent Development
  • Table 107. AGC Biologics Company Details
  • Table 108. AGC Biologics Business Overview
  • Table 109. AGC Biologics Biopharmaceutical CDMO Product
  • Table 110. AGC Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 111. AGC Biologics Recent Development
  • Table 112. Rentschler Biopharma Company Details
  • Table 113. Rentschler Biopharma Business Overview
  • Table 114. Rentschler Biopharma Biopharmaceutical CDMO Product
  • Table 115. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 116. Rentschler Biopharma Recent Development
  • Table 117. KBI Biopharma Company Details
  • Table 118. KBI Biopharma Business Overview
  • Table 119. KBI Biopharma Biopharmaceutical CDMO Product
  • Table 120. KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 121. Siegfried Company Details
  • Table 122. Siegfried Business Overview
  • Table 123. Siegfried Biopharmaceutical CDMO Product
  • Table 124. Siegfried Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 125. Siegfried Recent Development
  • Table 126. Aenova Group Company Details
  • Table 127. Aenova Group Business Overview
  • Table 128. Aenova Group Biopharmaceutical CDMO Product
  • Table 129. Aenova Group Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 130. GenScript Company Details
  • Table 131. GenScript Business Overview
  • Table 132. GenScript Biopharmaceutical CDMO Product
  • Table 133. GenScript Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 134. GenScript Recent Development
  • Table 135. ProBioGen Company Details
  • Table 136. ProBioGen Business Overview
  • Table 137. ProBioGen Biopharmaceutical CDMO Product
  • Table 138. ProBioGen Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 139. Northway Biotech Company Details
  • Table 140. Northway Biotech Business Overview
  • Table 141. Northway Biotech Biopharmaceutical CDMO Product
  • Table 142. Northway Biotech Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 143. Northway Biotech Recent Development
  • Table 144. 3P Biopharmaceuticals Company Details
  • Table 145. 3P Biopharmaceuticals Business Overview
  • Table 146. 3P Biopharmaceuticals Biopharmaceutical CDMO Product
  • Table 147. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million)
  • Table 148. Research Programs/Design for This Report
  • Table 149. Key Data Information from Secondary Sources
  • Table 150. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type, 2019-2030 (US$ Million)
  • Figure 2. Global Biopharmaceutical CDMO Market Share by Type: 2023 VS 2030
  • Figure 3. Cell and Gene Therapies Features
  • Figure 4. Antibodies Features
  • Figure 5. Vaccines Features
  • Figure 6. Other Features
  • Figure 7. Global Biopharmaceutical CDMO Market Size Growth Rate by Application, 2019-2030 (US$ Million)
  • Figure 8. Global Biopharmaceutical CDMO Market Share by Application: 2023 VS 2030
  • Figure 9. Biopharmaceutical CDMO Report Years Considered
  • Figure 10. Global Biopharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
  • Figure 11. Global Biopharmaceutical CDMO Market Size, (US$ Billion), 2019 VS 2023 VS 2030
  • Figure 12. Global Biopharmaceutical CDMO Market Share by Region in 2023
  • Figure 13. Global Biopharmaceutical CDMO Market Share by Players in 2023
  • Figure 14. The Top 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2023
  • Figure 15. The Top 10 Players Market Share by Biopharmaceutical CDMO Revenue in 2023
  • Figure 16. North America Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 17. North America Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • Figure 18. North America Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • Figure 19. North America Biopharmaceutical CDMO Market Share by Country (2019-2030)
  • Figure 20. United States Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 21. Canada Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 22. Mexico Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 23. Europe Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 24. Europe Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • Figure 25. Europe Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • Figure 26. Europe Biopharmaceutical CDMO Market Share by Country (2019-2030)
  • Figure 27. Germany Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 28. France Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 29. U.K. Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 30. Italy Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 31. Russia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 32. Asia-Pacific Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 33. Asia-Pacific Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • Figure 34. Asia-Pacific Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • Figure 35. Asia-Pacific Biopharmaceutical CDMO Market Share by Region (2019-2030)
  • Figure 36. China Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 37. Japan Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 38. South Korea Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 39. Southeast Asia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 40. India Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 41. Australia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 42. Latin America Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 43. Latin America Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • Figure 44. Latin America Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • Figure 45. Latin America Biopharmaceutical CDMO Market Share by Country (2019-2030)
  • Figure 46. Brazil Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 47. Argentina Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 48. Colombia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 49. Middle East and Africa Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 50. Middle East and Africa Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • Figure 51. Middle East and Africa Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • Figure 52. Middle East and Africa Biopharmaceutical CDMO Market Share by Country (2019-2030)
  • Figure 53. Middle East Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 54. Africa Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed 129
目次

The global Biopharmaceutical CDMO market is projected to grow from US$ 28.16 billion in 2024 to US$ 59.05 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 13.14% during the forecast period.

Report Includes:

This report presents an overview of global market for Biopharmaceutical CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Biopharmaceutical CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biopharmaceutical CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biopharmaceutical CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biopharmaceutical CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biopharmaceutical CDMO revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, and AGC Biologics, etc.

Market Segmentation

By Company

  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • WuXi AppTech
  • Recipharm
  • Thermo Fisher Scientific
  • AGC Biologics
  • Rentschler Biopharma
  • KBI Biopharma
  • Siegfried
  • Aenova Group
  • GenScript
  • ProBioGen
  • Northway Biotech
  • 3P Biopharmaceuticals

Segment by Type

  • Cell and Gene Therapies
  • Antibodies
  • Vaccines
  • Other

Segment by Application

  • SMBs
  • Large Companies

By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of APAC
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Rest of Europe
  • Latin America
    • Brazil
    • Argentina
    • Colombia
    • Rest of Latin America
  • Middle East & Africa
    • Middle East
    • Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Biopharmaceutical CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biopharmaceutical CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: Asia-Pacific by Type, and by Application, revenue for each segment.

Chapter 9: Latin America by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biopharmaceutical CDMO revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions.

Table of Contents

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
    • 1.2.2 Cell and Gene Therapies
    • 1.2.3 Antibodies
    • 1.2.4 Vaccines
    • 1.2.5 Other
  • 1.3 Market by Application
    • 1.3.1 Global Biopharmaceutical CDMO Market Share by Application: 2019 VS 2023 VS 2030
    • 1.3.2 SMBs
    • 1.3.3 Large Companies
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Biopharmaceutical CDMO Market Perspective (2019-2030)
  • 2.2 Global Biopharmaceutical CDMO Growth Trends by Region
    • 2.2.1 Global Biopharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
    • 2.2.2 Biopharmaceutical CDMO Historic Market Size by Region (2019-2024)
    • 2.2.3 Biopharmaceutical CDMO Forecasted Market Size by Region (2025-2030)
  • 2.3 Biopharmaceutical CDMO Market Dynamics
    • 2.3.1 Biopharmaceutical CDMO Industry Trends
    • 2.3.2 Biopharmaceutical CDMO Market Drivers
    • 2.3.3 Biopharmaceutical CDMO Market Challenges
    • 2.3.4 Biopharmaceutical CDMO Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Revenue Biopharmaceutical CDMO by Players
    • 3.1.1 Global Biopharmaceutical CDMO Revenue by Players (2019-2024)
    • 3.1.2 Global Biopharmaceutical CDMO Revenue Market Share by Players (2019-2024)
  • 3.2 Global Biopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Global Key Players of Biopharmaceutical CDMO, Ranking by Revenue, 2022 VS 2023
  • 3.4 Global Biopharmaceutical CDMO Market Concentration Ratio
    • 3.4.1 Global Biopharmaceutical CDMO Market Concentration Ratio (CR5)
    • 3.4.2 Global Top 5 and Top 10 Companies by Biopharmaceutical CDMO Revenue in 2023
  • 3.5 Global Key Players of Biopharmaceutical CDMO Head office and Area Served
  • 3.6 Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry
  • 3.7 Mergers & Acquisitions, Expansion Plans

4 Biopharmaceutical CDMO Breakdown Data by Type

  • 4.1 Global Biopharmaceutical CDMO Historic Market Size by Type (2019-2024)
  • 4.2 Global Biopharmaceutical CDMO Forecasted Market Size by Type (2025-2030)

5 Biopharmaceutical CDMO Breakdown Data by Application

  • 5.1 Global Biopharmaceutical CDMO Historic Market Size by Application (2019-2024)
  • 5.2 Global Biopharmaceutical CDMO Forecasted Market Size by Application (2025-2030)

6 North America

  • 6.1 North America Biopharmaceutical CDMO Market Size (2019-2030)
  • 6.2 North America Biopharmaceutical CDMO Market Size by Type
    • 6.2.1 North America Biopharmaceutical CDMO Market Size by Type (2019-2024)
    • 6.2.2 North America Biopharmaceutical CDMO Market Size by Type (2025-2030)
    • 6.2.3 North America Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • 6.3 North America Biopharmaceutical CDMO Market Size by Application
    • 6.3.1 North America Biopharmaceutical CDMO Market Size by Application (2019-2024)
    • 6.3.2 North America Biopharmaceutical CDMO Market Size by Application (2025-2030)
    • 6.3.3 North America Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • 6.4 North America Biopharmaceutical CDMO Market Size by Country
    • 6.4.1 North America Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
    • 6.4.2 North America Biopharmaceutical CDMO Market Size by Country (2019-2024)
    • 6.4.3 North America Biopharmaceutical CDMO Market Share by Country (2025-2030)
    • 6.4.4 United States
    • 6.4.5 Canada
    • 6.4.6 Mexico

7 Europe

  • 7.1 Europe Biopharmaceutical CDMO Market Size (2019-2030)
  • 7.2 Europe Biopharmaceutical CDMO Market Size by Type
    • 7.2.1 Europe Biopharmaceutical CDMO Market Size by Type (2019-2024)
    • 7.2.2 Europe Biopharmaceutical CDMO Market Size by Type (2025-2030)
    • 7.2.3 Europe Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • 7.3 Europe Biopharmaceutical CDMO Market Size by Application
    • 7.3.1 Europe Biopharmaceutical CDMO Market Size by Application (2019-2024)
    • 7.3.2 Europe Biopharmaceutical CDMO Market Size by Application (2025-2030)
    • 7.3.3 Europe Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • 7.4 Europe Biopharmaceutical CDMO Market Size by Country
    • 7.4.1 Europe Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
    • 7.4.2 Europe Biopharmaceutical CDMO Market Size by Country (2019-2024)
    • 7.4.3 Europe Biopharmaceutical CDMO Market Size by Country (2025-2030)
    • 7.4.4 Germany
    • 7.4.5 France
    • 7.4.6 U.K.
    • 7.4.7 Italy
    • 7.4.8 Russia

8 Asia-Pacific

  • 8.1 Asia-Pacific Biopharmaceutical CDMO Market Size (2019-2030)
  • 8.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Type
    • 8.2.1 Asia-Pacific Biopharmaceutical CDMO Market Size by Type (2019-2024)
    • 8.2.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Type (2025-2030)
    • 8.2.3 Asia-Pacific Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • 8.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Application
    • 8.3.1 Asia-Pacific Biopharmaceutical CDMO Market Size by Application (2019-2024)
    • 8.3.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Application (2025-2030)
    • 8.3.3 Asia-Pacific Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • 8.4 Asia-Pacific Biopharmaceutical CDMO Market Size by Region
    • 8.4.1 Asia-Pacific Biopharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
    • 8.4.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2019-2024)
    • 8.4.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2025-2030)
    • 8.4.4 China
    • 8.4.5 Japan
    • 8.4.6 South Korea
    • 8.4.7 Southeast Asia
    • 8.4.8 India
    • 8.4.9 Australia

9 Latin America

  • 9.1 Latin America Biopharmaceutical CDMO Market Size (2019-2030)
  • 9.2 Latin America Biopharmaceutical CDMO Market Size by Type
    • 9.2.1 Latin America Biopharmaceutical CDMO Market Size by Type (2019-2024)
    • 9.2.2 Latin America Biopharmaceutical CDMO Market Size by Type (2025-2030)
    • 9.2.3 Latin America Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • 9.3 Latin America Biopharmaceutical CDMO Market Size by Application
    • 9.3.1 Latin America Biopharmaceutical CDMO Market Size by Application (2019-2024)
    • 9.3.2 Latin America Biopharmaceutical CDMO Market Size by Application (2025-2030)
    • 9.3.3 Latin America Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • 9.4 Latin America Biopharmaceutical CDMO Market Size by Country
    • 9.4.1 Latin America Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
    • 9.4.2 Latin America Biopharmaceutical CDMO Market Size by Country (2019-2024)
    • 9.4.3 Latin America Biopharmaceutical CDMO Market Size by Country (2025-2030)
    • 9.4.4 Brazil
    • 9.4.5 Argentina
    • 9.4.6 Colombia

10 Middle East and Africa

  • 10.1 Middle East and Africa Biopharmaceutical CDMO Market Size (2019-2030)
  • 10.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Type
    • 10.2.1 Middle East and Africa Biopharmaceutical CDMO Market Size by Type (2019-2024)
    • 10.2.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Type (2025-2030)
    • 10.2.3 Middle East and Africa Biopharmaceutical CDMO Market Share by Type (2019-2030)
  • 10.3 Middle East and Africa Biopharmaceutical CDMO Market Size by Application
    • 10.3.1 Middle East and Africa Biopharmaceutical CDMO Market Size by Application (2019-2024)
    • 10.3.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Application (2025-2030)
    • 10.3.3 Middle East and Africa Biopharmaceutical CDMO Market Share by Application (2019-2030)
  • 10.4 Middle East and Africa Biopharmaceutical CDMO Market Size by Country
    • 10.4.1 Middle East and Africa Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
    • 10.4.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Country (2019-2024)
    • 10.4.3 Middle East and Africa Biopharmaceutical CDMO Market Size by Country (2025-2030)
    • 10.4.4 Middle East
    • 10.4.5 Africa

11 Key Players Profiles

  • 11.1 Lonza
    • 11.1.1 Lonza Company Details
    • 11.1.2 Lonza Business Overview
    • 11.1.3 Lonza Biopharmaceutical CDMO Introduction
    • 11.1.4 Lonza Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.1.5 Lonza Recent Development
  • 11.2 Catalent
    • 11.2.1 Catalent Company Details
    • 11.2.2 Catalent Business Overview
    • 11.2.3 Catalent Biopharmaceutical CDMO Introduction
    • 11.2.4 Catalent Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.2.5 Catalent Recent Development
  • 11.3 Samsung Biologics
    • 11.3.1 Samsung Biologics Company Details
    • 11.3.2 Samsung Biologics Business Overview
    • 11.3.3 Samsung Biologics Biopharmaceutical CDMO Introduction
    • 11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.3.5 Samsung Biologics Recent Development
  • 11.4 FUJIFILM Diosynth Biotechnologies
    • 11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
    • 11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
    • 11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Introduction
    • 11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
  • 11.5 Boehringer Ingelheim
    • 11.5.1 Boehringer Ingelheim Company Details
    • 11.5.2 Boehringer Ingelheim Business Overview
    • 11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Introduction
    • 11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.5.5 Boehringer Ingelheim Recent Development
  • 11.6 WuXi AppTech
    • 11.6.1 WuXi AppTech Company Details
    • 11.6.2 WuXi AppTech Business Overview
    • 11.6.3 WuXi AppTech Biopharmaceutical CDMO Introduction
    • 11.6.4 WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.6.5 WuXi AppTech Recent Development
  • 11.7 Recipharm
    • 11.7.1 Recipharm Company Details
    • 11.7.2 Recipharm Business Overview
    • 11.7.3 Recipharm Biopharmaceutical CDMO Introduction
    • 11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.7.5 Recipharm Recent Development
  • 11.8 Thermo Fisher
    • 11.8.1 Thermo Fisher Company Details
    • 11.8.2 Thermo Fisher Business Overview
    • 11.8.3 Thermo Fisher Biopharmaceutical CDMO Introduction
    • 11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.8.5 Thermo Fisher Recent Development
  • 11.9 AGC Biologics
    • 11.9.1 AGC Biologics Company Details
    • 11.9.2 AGC Biologics Business Overview
    • 11.9.3 AGC Biologics Biopharmaceutical CDMO Introduction
    • 11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.9.5 AGC Biologics Recent Development
  • 11.10 Rentschler Biopharma
    • 11.10.1 Rentschler Biopharma Company Details
    • 11.10.2 Rentschler Biopharma Business Overview
    • 11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Introduction
    • 11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.10.5 Rentschler Biopharma Recent Development
  • 11.11 KBI Biopharma
    • 11.11.1 KBI Biopharma Company Details
    • 11.11.2 KBI Biopharma Business Overview
    • 11.11.3 KBI Biopharma Biopharmaceutical CDMO Introduction
    • 11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024)
  • 11.12 Siegfried
    • 11.12.1 Siegfried Company Details
    • 11.12.2 Siegfried Business Overview
    • 11.12.3 Siegfried Biopharmaceutical CDMO Introduction
    • 11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.12.5 Siegfried Recent Development
  • 11.13 Aenova Group
    • 11.13.1 Aenova Group Company Details
    • 11.13.2 Aenova Group Business Overview
    • 11.13.3 Aenova Group Biopharmaceutical CDMO Introduction
    • 11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Business (2019-2024)
  • 11.14 GenScript
    • 11.14.1 GenScript Company Details
    • 11.14.2 GenScript Business Overview
    • 11.14.3 GenScript Biopharmaceutical CDMO Introduction
    • 11.14.4 GenScript Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.14.5 GenScript Recent Development
  • 11.15 ProBioGen
    • 11.15.1 ProBioGen Company Details
    • 11.15.2 ProBioGen Business Overview
    • 11.15.3 ProBioGen Biopharmaceutical CDMO Introduction
    • 11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Business (2019-2024)
  • 11.16 Northway Biotech
    • 11.16.1 Northway Biotech Company Details
    • 11.16.2 Northway Biotech Business Overview
    • 11.16.3 Northway Biotech Biopharmaceutical CDMO Introduction
    • 11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Business (2019-2024)
    • 11.16.5 Northway Biotech Recent Development
  • 11.17 3P Biopharmaceuticals
    • 11.17.1 3P Biopharmaceuticals Company Details
    • 11.17.2 3P Biopharmaceuticals Business Overview
    • 11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Introduction
    • 11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2019-2024)

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer